- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.84 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x CA: CALCIUM ION(Non-covalent)
- 4 x EF8: 6-[[(3~{R},4~{R},5~{S})-4-acetamido-5-azanyl-3-pentan-3-yloxy-cyclohexen-1-yl]-oxidanyl-phosphoryl]oxyhexylimino-azanylidene-azanium(Non-covalent)
EF8.2: 15 residues within 4Å:- Chain A: R.37, E.38, I.68, D.70, R.71, W.98, R.144, S.166, E.196, E.197, R.212, N.214, R.287, Y.321, P.350
14 PLIP interactions:14 interactions with chain A- Hydrophobic interactions: A:W.98, A:E.196, A:P.350
- Hydrogen bonds: A:R.37, A:R.37, A:E.38, A:R.71, A:R.212, A:R.212, A:R.287, A:R.287
- Water bridges: A:R.75, A:E.197, A:E.197
EF8.13: 15 residues within 4Å:- Chain B: R.37, E.38, I.68, D.70, R.71, W.98, R.144, S.166, E.196, E.197, R.212, N.214, R.287, Y.321, P.350
14 PLIP interactions:14 interactions with chain B- Hydrophobic interactions: B:W.98, B:E.196, B:P.350
- Hydrogen bonds: B:R.37, B:R.37, B:E.38, B:R.71, B:R.212, B:R.212, B:R.287, B:R.287
- Water bridges: B:R.75, B:E.197, B:E.197
EF8.24: 15 residues within 4Å:- Chain C: R.37, E.38, I.68, D.70, R.71, W.98, R.144, S.166, E.196, E.197, R.212, N.214, R.287, Y.321, P.350
14 PLIP interactions:14 interactions with chain C- Hydrophobic interactions: C:W.98, C:E.196, C:P.350
- Hydrogen bonds: C:R.37, C:R.37, C:E.38, C:R.71, C:R.212, C:R.212, C:R.287, C:R.287
- Water bridges: C:R.75, C:E.197, C:E.197
EF8.35: 15 residues within 4Å:- Chain D: R.37, E.38, I.68, D.70, R.71, W.98, R.144, S.166, E.196, E.197, R.212, N.214, R.287, Y.321, P.350
14 PLIP interactions:14 interactions with chain D- Hydrophobic interactions: D:W.98, D:E.196, D:P.350
- Hydrogen bonds: D:R.37, D:R.37, D:E.38, D:R.71, D:R.212, D:R.212, D:R.287, D:R.287
- Water bridges: D:R.75, D:E.197, D:E.197
- 12 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.3: 2 residues within 4Å:- Chain A: N.7, S.8
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:N.7
NAG.4: 4 residues within 4Å:- Chain A: K.62, N.65, I.355
- Ligands: EDO.11
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:I.355
- Hydrogen bonds: A:N.65
NAG.5: 2 residues within 4Å:- Chain A: N.154, Q.227
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:K.3, A:N.154, A:Q.227
NAG.14: 2 residues within 4Å:- Chain B: N.7, S.8
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:N.7
NAG.15: 4 residues within 4Å:- Chain B: K.62, N.65, I.355
- Ligands: EDO.22
2 PLIP interactions:2 interactions with chain B- Hydrophobic interactions: B:I.355
- Hydrogen bonds: B:N.65
NAG.16: 2 residues within 4Å:- Chain B: N.154, Q.227
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:K.3, B:N.154, B:Q.227
NAG.25: 2 residues within 4Å:- Chain C: N.7, S.8
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:N.7
NAG.26: 4 residues within 4Å:- Chain C: K.62, N.65, I.355
- Ligands: EDO.33
2 PLIP interactions:2 interactions with chain C- Hydrophobic interactions: C:I.355
- Hydrogen bonds: C:N.65
NAG.27: 2 residues within 4Å:- Chain C: N.154, Q.227
3 PLIP interactions:3 interactions with chain C- Hydrogen bonds: C:K.3, C:N.154, C:Q.227
NAG.36: 2 residues within 4Å:- Chain D: N.7, S.8
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:N.7
NAG.37: 4 residues within 4Å:- Chain D: K.62, N.65, I.355
- Ligands: EDO.44
2 PLIP interactions:2 interactions with chain D- Hydrophobic interactions: D:I.355
- Hydrogen bonds: D:N.65
NAG.38: 2 residues within 4Å:- Chain D: N.154, Q.227
3 PLIP interactions:3 interactions with chain D- Hydrogen bonds: D:K.3, D:N.154, D:Q.227
- 24 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.6: 6 residues within 4Å:- Chain A: L.46, E.47, C.48
- Chain C: N.128, G.129, I.130
Ligand excluded by PLIPEDO.7: 6 residues within 4Å:- Chain A: R.26
- Chain C: N.65, G.66, T.67, K.69, S.72
Ligand excluded by PLIPEDO.8: 5 residues within 4Å:- Chain A: P.81, E.84
- Chain C: Y.89, N.90, S.91
Ligand excluded by PLIPEDO.9: 5 residues within 4Å:- Chain A: P.12, V.13, Y.272, W.277, W.294
Ligand excluded by PLIPEDO.10: 8 residues within 4Å:- Chain A: W.16, A.17, I.18, Q.310, T.371, V.372, W.376
- Chain C: V.124
Ligand excluded by PLIPEDO.11: 5 residues within 4Å:- Chain A: N.65, R.349, T.354, I.355
- Ligands: NAG.4
Ligand excluded by PLIPEDO.17: 6 residues within 4Å:- Chain B: L.46, E.47, C.48
- Chain D: N.128, G.129, I.130
Ligand excluded by PLIPEDO.18: 6 residues within 4Å:- Chain B: R.26
- Chain D: N.65, G.66, T.67, K.69, S.72
Ligand excluded by PLIPEDO.19: 5 residues within 4Å:- Chain B: P.81, E.84
- Chain D: Y.89, N.90, S.91
Ligand excluded by PLIPEDO.20: 5 residues within 4Å:- Chain B: P.12, V.13, Y.272, W.277, W.294
Ligand excluded by PLIPEDO.21: 8 residues within 4Å:- Chain B: W.16, A.17, I.18, Q.310, T.371, V.372, W.376
- Chain D: V.124
Ligand excluded by PLIPEDO.22: 5 residues within 4Å:- Chain B: N.65, R.349, T.354, I.355
- Ligands: NAG.15
Ligand excluded by PLIPEDO.28: 6 residues within 4Å:- Chain B: N.128, G.129, I.130
- Chain C: L.46, E.47, C.48
Ligand excluded by PLIPEDO.29: 6 residues within 4Å:- Chain B: N.65, G.66, T.67, K.69, S.72
- Chain C: R.26
Ligand excluded by PLIPEDO.30: 5 residues within 4Å:- Chain B: Y.89, N.90, S.91
- Chain C: P.81, E.84
Ligand excluded by PLIPEDO.31: 5 residues within 4Å:- Chain C: P.12, V.13, Y.272, W.277, W.294
Ligand excluded by PLIPEDO.32: 8 residues within 4Å:- Chain B: V.124
- Chain C: W.16, A.17, I.18, Q.310, T.371, V.372, W.376
Ligand excluded by PLIPEDO.33: 5 residues within 4Å:- Chain C: N.65, R.349, T.354, I.355
- Ligands: NAG.26
Ligand excluded by PLIPEDO.39: 6 residues within 4Å:- Chain A: N.128, G.129, I.130
- Chain D: L.46, E.47, C.48
Ligand excluded by PLIPEDO.40: 6 residues within 4Å:- Chain A: N.65, G.66, T.67, K.69, S.72
- Chain D: R.26
Ligand excluded by PLIPEDO.41: 5 residues within 4Å:- Chain A: Y.89, N.90, S.91
- Chain D: P.81, E.84
Ligand excluded by PLIPEDO.42: 5 residues within 4Å:- Chain D: P.12, V.13, Y.272, W.277, W.294
Ligand excluded by PLIPEDO.43: 8 residues within 4Å:- Chain A: V.124
- Chain D: W.16, A.17, I.18, Q.310, T.371, V.372, W.376
Ligand excluded by PLIPEDO.44: 5 residues within 4Å:- Chain D: N.65, R.349, T.354, I.355
- Ligands: NAG.37
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kozisek, M. et al., DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors. Biochem. J. (2018)
- Release Date
- 2019-01-23
- Peptides
- Neuraminidase: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
AC
AD
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.84 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x CA: CALCIUM ION(Non-covalent)
- 4 x EF8: 6-[[(3~{R},4~{R},5~{S})-4-acetamido-5-azanyl-3-pentan-3-yloxy-cyclohexen-1-yl]-oxidanyl-phosphoryl]oxyhexylimino-azanylidene-azanium(Non-covalent)
- 12 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 24 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kozisek, M. et al., DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors. Biochem. J. (2018)
- Release Date
- 2019-01-23
- Peptides
- Neuraminidase: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
AC
AD
A